ERBB2 and neoplasm: Tumor biology played a significant role as well: patients with ER-/HER2+ tumors had the greatest likelihood of nodal pCR (OR = 3.34, 95%CI: 2.02–5.52, p < 0.0001), followed by ER+/HER2+ tumors (OR = 2.40, 95%CI: 1.58–3.65, p < 0.0001) and triple-negative tumors (OR = 1.94, 95%CI: 1.34–2.81, p = 0.0004).